NeoGraph Analytics
PharmaceuticalsNorth America2023 – 2032

Asia Pacific Antibody Drug Conjugates Industry Size, Competitive Landscape and Regional Analysis

Asia Pacific Antibody Drug Conjugates market valued at $2.5B in 2023, projected to reach $9.9B by 2032 at 16.5% CAGR.

Revenue, 2023

$2.5B

Forecast, 2032

$9.9B

CAGR, 2024-2032

16.5%

Report Coverage

North America

Code: asia-pacific-antibody-drug-conjugates-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The Asia Pacific Antibody Drug Conjugates market was valued at approximately $2.5 billion in 2023 and is projected to reach $9.9 billion by 2032, growing at a CAGR of 16.5%. China and Japan collectively account for over 63% of regional revenue. Rising oncology prevalence, expanding biologic manufacturing infrastructure, and accelerated regulatory approvals are primary growth catalysts. AstraZeneca/Daiichi Sankyo's Enhertu and Roche's Kadcyla dominate the competitive landscape.

02

Key Highlights

1

Asia Pacific ADC market projected to grow from $2.5B in 2023 to $9.9B by 2032 at 16.5% CAGR.

2

China dominates with 35% regional share, driven by large patient populations and local manufacturing.

3

Next-generation ADCs with novel linkers and payloads are expanding beyond oncology into new therapeutic areas.

03

Market Overview

Market Context

The Asia Pacific ADC market is experiencing rapid growth fueled by rising cancer incidence, expanding biomanufacturing infrastructure, and accelerated regulatory pathways in China and Japan. Key markets include China, Japan, India, and South Korea.

The Asia Pacific ADC market is in a high-growth phase driven by increasing cancer incidence, rising biosimilar adoption, and expanding local manufacturing. China leads regional demand, followed by Japan and India. The market is expected to nearly quadruple from 2023 to 2032.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Tumor-agnostic ADC approvals expanding addressable patient populationsChinese biotech firms advancing novel ADC candidates through clinical trialsRising CDMO partnerships enabling cost-effective ADC manufacturing in India and ChinaNext-generation linker-payload technologies improving therapeutic windows
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 16.5%

Base Year (2023)

$2.5B

Forecast (2032)

$9.9B

CAGR (2024-2032)

16.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$2.50B
2024$2.91B
2025$3.39B
2026$3.95B
2027$4.61B
2028$5.36B
2029$6.25B
2030$7.28B
2031$8.48B
2032$9.88B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

With a 16.5% CAGR, the Asia Pacific ADC market is expected to nearly quadruple from 2023 to 2032. China and India will drive the fastest growth due to expanding healthcare expenditure and increasing clinical trial activity for novel ADC candidates.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America45.0%14.2%United States
Europe28.0%13.8%Germany
Asia Pacific27.0%18.3%China

North America

#1
Share: 45.0%CAGR: 14.2%

Largest market: United States

Europe

#2
Share: 28.0%CAGR: 13.8%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising cancer incidence across China, India, and Japan
  • Accelerated regulatory approvals for oncology biologics
  • Expanding local ADC manufacturing capabilities
06

Market Segmentation

By Component
Market share distribution across 4 segments
By Component — market share by segment, in percent.
SegmentShare
Monoclonal AntibodiesLargest component segment as the targeting moiety in all approved ADCs.45.0%
Cytotoxic DrugsPayload segment including auristatins, maytansinoids, and topoisomerase inhibitors.30.0%
LinkersCleavable and non-cleavable linker technologies critical for ADC stability and efficacy.15.0%
OthersCovers conjugation technologies and formulation components.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Indication
Market share distribution across 5 segments
By Indication — market share by segment, in percent.
SegmentShare
Breast CancerLargest segment driven by HER2-targeting ADCs such as Kadcyla and Enhertu with strong reimbursement coverage.40.0%
Hematologic MalignanciesGrowing adoption of CD30 and CD19-targeting ADCs for lymphoma and leukemia indications.25.0%
Lung CancerEmerging ADC therapies targeting HER2-mutant and TROP2-expressing non-small cell lung cancers.18.0%
Gynecological CancerADC pipeline expanding in ovarian and cervical cancer indications across the region.10.0%
OthersIncludes gastric, urothelial, and other solid tumor indications with early-stage ADC adoption.7.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals
  • Specialty Clinics
  • Research Institutes
07

Regional Analysis

1

North America

Lead: United States
CAGR: 14.2%Share: 45.0%

Mature ADC market led by Kadcyla and Adcetris with established reimbursement frameworks.

2

Europe

Lead: Germany
CAGR: 13.8%Share: 28.0%

Growing adoption supported by EMA fast-track approvals and expanding oncology budgets.

3

Asia Pacific

Lead: China
CAGR: 18.3%Share: 27.0%

Fastest-growing region driven by rising cancer burden, biosimilar development, and expanding biomanufacturing capacity.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
China
35.0%
+18.0%
Japan
28.0%
+14.0%
India
18.0%
+19.5%
Australia
10.0%
+13.0%
South Korea
9.0%
+15.0%
08

Competitive Landscape

R

Roche (Genentech)

Switzerland

Leader60.1B

Dominates with Kadcyla, the first approved ADC, generating the largest single-product revenue in the breast cancer segment globally and across APAC.

Global pioneer in ADC technology with Kadcyla as the flagship product, commanding the largest market share in the Asia Pacific breast cancer ADC segment.

A

AstraZeneca / Daiichi Sankyo

United Kingdom / Japan

Challenger45.0B

Fastest-growing ADC portfolio led by Enhertu, with tumor-agnostic approvals significantly expanding total addressable market across Asia Pacific.

Fastest-growing ADC partnership leveraging Enhertu's tumor-agnostic approval to capture expanding patient populations across China, Japan, and South Korea.

P

Pfizer (Seagen)

United States

Follower

Acquired Seagen in 2023 to gain Adcetris and a robust ADC pipeline, strengthening oncology presence in the Asia Pacific region.

Also profiled

H

Hengrui Medicine

1.2B

Leading Chinese biopharmaceutical company advancing multiple ADC candidates including RC48 (disitamab vedotin), with strong domestic commercial presence and growing international partnerships.

09

Recent Developments

25
2025AstraZeneca / Daiichi Sankyo

Enhertu received tumor-agnostic expanded approval in Japan and South Korea, significantly broadening the eligible patient population across Asia Pacific.

24
2024Hengrui Medicine

RC48 (disitamab vedotin) received NMPA approval for biliary tract cancer in China, marking a key milestone for locally developed ADCs in the region.

10

Regulatory Landscape

NMPA (China) accelerated approval pathway for oncology biologics reducing time-to-market for novel ADCsPMDA (Japan) Sakigake designation enabling priority review for innovative ADC therapies
11

Research Methodology

Primary research

  • Expert interviews with oncologists and pharma executives
  • Surveys with hospital procurement officers

Secondary research

  • Industry reports from MarketsandMarkets and Technavio
  • Company financial filings and annual reports

Validation: Triangulation method

12

Strategic Takeaways

Investors

The Asia Pacific ADC market offers high-growth potential with a 16.5% CAGR through 2032, particularly in China and India.

Operators

Local manufacturing partnerships and biosimilar ADC development are critical strategies for capturing market share in the region.

Policymakers

Streamlined regulatory pathways in China and Japan are accelerating ADC adoption and should be leveraged for faster patient access.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.